Business Context and Reporting Period
Company: Wilson Greatbatch Technologies, Inc. (Note: Metadata listed "Integer Holdings Corp" is incorrect; the filing is for Wilson Greatbatch).
Filing Type: Form 10-Q (Quarterly Report).
Reporting Period: Quarter and six months ended June 30, 2003 (Fiscal year ends the Friday nearest December 31).
Business Overview: The Company designs and manufactures batteries, capacitors, and components for implantable medical devices (Cardiac Rhythm Management) and high-performance batteries for commercial applications (oil/gas, aerospace).
Key Financial Metrics
| Metric | Three Months Ended June 30, 2003 | Six Months Ended June 30, 2003 |
|---|---|---|
| Sales | $55.8 million | $110.7 million |
| Gross Profit | $23.2 million | $46.0 million |
| Gross Margin | 41.5% | 41.6% |
| Operating Income | $9.5 million | $19.3 million |
| Operating Margin | 17.1% | 17.4% |
| Net Income | $5.0 million | $11.0 million |
| Diluted EPS | $0.23 | $0.51 |
| Cash from Operations (6mo) | $19.8 million | |
| Cash & Equivalents (End of Period) | $99.5 million | |
| Total Debt (Long-term + Current) | $171.4 million |
Material Changes vs. Prior Period
- Revenue Growth: Sales increased 46% year-over-year for the quarter and 48% for the six-month period. Medical technology sales drove growth, up 38% (quarter) and 41% (six months), while commercial power sources remained relatively flat.
- Profitability: Net income rose 38% for the quarter and 59% for the six-month period compared to the prior year. Operating income increased 60% (quarter) and 65% (six months).
- Debt Restructuring: In May 2003, the Company issued $170 million in 2.25% convertible subordinated notes due 2013. Proceeds were used to pay off a $72.5 million term loan. This resulted in a $1.6 million charge for early extinguishment of debt.
- Liquidity: Cash and cash equivalents surged from $4.6 million at year-end 2002 to $99.5 million at June 30, 2003, primarily due to the debt issuance. The current ratio improved from less than 3:1 to greater than 8:1.
- Asset Sale: The Company sold assets related to its commercial capacitor product line for approximately $2.3 million with no material gain or loss.
Guidance, Outlook, and Risks
- Outlook: Management anticipates higher capital spending in 2003 for IT infrastructure and a new medical battery manufacturing plant. The Company is actively discussing potential acquisitions and believes its capital structure positions it well for future growth.
- Segment Performance: Growth in the medical segment is attributed to volume increases in ICD batteries, pacemaker batteries, and components (including enclosures from the Greatbatch-Globe acquisition). Commercial sales improved due to steady demand in the oil and gas sector.
- Risks: Key risks include dependence on a limited number of customers, product obsolescence, pricing pressure, reliance on third-party suppliers, and regulatory changes in the healthcare industry.
- Unusual Items: The $1.6 million charge for debt extinguishment and the write-off of deferred financing fees impacted the quarter's results. Stock-based compensation pro-forma adjustments would reduce reported net income slightly.
Investor Verification Checklist
- Debt Terms: Verify the conversion triggers and redemption rights of the new $170 million convertible notes (due 2013).
- Customer Concentration: Assess the impact of the "limited number of customers" risk on future revenue stability.
- Capital Expenditures: Monitor actual spending against the anticipated increase for the new medical battery plant and IT infrastructure.
- Acquisition Activity: Watch for announcements regarding potential acquisitions, as the Company has identified opportunities and has significant liquidity.
- Margin Sustainability: Evaluate whether the gross margin improvements in EMI filtered feedthroughs are sustainable or offset by integration costs from recent acquisitions.